Answers are grounded in this paper and cite their sources.
Prospective survey evaluates medication cessation in cystic fibrosis patients after elexacaftor/tezacaftor/ivacaftor, suggesting streamlined treatments.
Chloride channel potentiator and corrector elexacaftor/tezacaftor/ivacaftor (ETI) has reduced the burden of disease in people with cystic fibrosis (PwCF) and led to some patients ceasing high‐burden treatment regimens. This study was a prospective survey and qualitative interview that evaluated medications PwCF had ceased after ETI. It demonstrated that a majority of PwCF have ceased medications, which prompts further research to rationalise medication regimens for PwCF.
No takes yet. Share an insight, caveat, or question.
Corbett et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: